14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XOMA vs DMAC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (46.3/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 2–8 (led by Options & Positioning), while XOMA wins 4–1 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (2–8 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.9% operating margin) and revenue trajectory (+0.0% vs. -22.6% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs DMAC. Trailing 12-month operating profitability (XOMA -3.9% vs DMAC 0.0%) and valuation multiples (XOMA 21.5x vs DMAC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XOMA vs DMAC Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (46.3/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 2–8 (led by Options & Positioning), while XOMA wins 4–1 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (2–8 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.9% operating margin) and revenue trajectory (+0.0% vs. -22.6% YoY).
XOMA leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus N/A for DMAC. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.
XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus DMAC (-114.6% ROE) capital efficiency.
In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.